Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-complex 11 family, X-linked 2 (TCP11X2) is a protein-coding gene located on the X chromosome and is a member of the T-complex protein family. It is predicted to be involved in protein kinase A signaling and the regulation of sperm capacitation, with activity suggested in the acrosomal vesicle and the flagellum of sperm cells. TCP11X2 has no direct evidence of involvement as a receptor, enzyme, transporter, or direct therapeutic target. The gene is expressed mainly in testis and is primarily linked to reproductive system function. Currently, there are no known drugs, disease biomarkers, or established disease associations linked to TCP11X2, and no notable therapeutic safety concerns are reported. While "regulation of sperm capacitation" and "protein kinase A signaling" are listed as predicted functions, the mechanistic details and experimental evidence are limited; most annotations are based on sequence and domain prediction, not established experimental validation. TCP11X2 is not classified as a classic therapeutic target (receptor, enzyme, etc.), nor are there clinical drugs targeting it, though it may still be of interest for basic sperm biology research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-complex 11 family, X-linked 2 (TCP11X2).